2月19日 - ** 券商 Piper Sandler 启动对药物开发商 Compass Therapeutics CMPX.O的评级，给予 "增持 "评级，目标价为 12 美元。
** 券商称，该公司主导药物 tovecimig 的中后期试验结果可能有助于提振股价
** 补充说，如果该药在提高总体反应率（即对治疗有反应的患者比例）方面的效果超过 23%，那将是一场 "胜利
** 该药与紫杉醇化疗联合治疗胆道癌的试验数据令人鼓舞
** 这表明其中后期阶段的试验结果(，预计将于 3 月公布)，其疗效也将支持监管机构的批准 - Piper Sandler
** 如果被批准作为胆道癌的二线治疗药物，预计美国销售额最高可达 6.35 亿美元。
** 公司还在对结肠直肠癌患者进行药物测试
** 过去 12 个月股价上涨了 71.3
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.